Abonnement à la biblothèque: Guest
Portail numérique Bibliothèque numérique eBooks Revues Références et comptes rendus Collections
International Journal of Physiology and Pathophysiology
SJR: 0.116

ISSN Imprimer: 2155-014X
ISSN En ligne: 2155-0158

Archives: Volume 1, 2010 to Volume 9, 2018

International Journal of Physiology and Pathophysiology

DOI: 10.1615/IntJPhysPathophys.v5.i2.80
pages 171-182

Mesenchymal Stem Cells and Their Immune Properties

Mykola I. Lisianyi
Romodanov Institute of Neurosurgery, National Academy of Medical Sciences of Ukraine, Kyiv, Ukraine

RÉSUMÉ

Mesenchymal stem cells (MSC) are available in various body tissues, including bone marrow, adipose tissue, and skin. They can multiply not only at in vivo conditions, but also in vitro. MSCs have great regenerative potential, and they are able to proliferate into different types of tissues. Moreover, MSCs exhibit pronounced immunosuppressive properties and can inhibit the functioning of various immune cells, especially T-lymphocytes, killer and dendritic cells. These properties have being used in clinical applications to inhibit autoimmune responses and bone marrow rejection reactions. It has been shown that MSC immunosuppression is achieved through the synthesis of humoral factors such as cytokines, indolamino-2,3-dioxygenase (IDO), nitric oxide, human leucocyte antigen G (HLA-G), interleukines. In case of using MSCs to treat myocardial infarction in rats, these cells are transformed into myocytes, they change their antigenic profile, losing the ability to inhibit immune responses, which leads to rejection. These facts are important to elucidate the mechanism of their action and use in clinical practice for both immunosuppression and stem cell therapy.


Articles with similar content:

Immune Responses to BRAF-Targeted Therapy in Melanoma: Is Targeted Therapy Immunotherapy?
Critical Reviews™ in Oncogenesis, Vol.21, 2016, issue 1-2
Mark C. Kelley
Induction of RKIP Expression by Anticancer Therapeutic Antibodies and Its Role in the Reversal of Chemo- and Immunoresistance
Forum on Immunopathological Diseases and Therapeutics, Vol.2, 2011, issue 2
Benjamin Bonavida
Therapeutic YY1 Inhibitors in Cancer: ALL in ONE
Critical Reviews™ in Oncogenesis, Vol.22, 2017, issue 1-2
Benjamin Bonavida
Toll-like Receptor Modulation in Head and Neck Cancer
Critical Reviews™ in Immunology, Vol.28, 2008, issue 3
Barbara Wollenberg, Sandra Wulff, Ralph Pries
Multiple Defects of Natural Killer Cells in Cancer Patients: Anarchy, Dysregulated Systemic Immunity, and Immunosuppression in Metastatic Cancer
Critical Reviews™ in Immunology, Vol.40, 2020, issue 2
Tamara Lah Turnsek, Barbara Breznik, Meng-Wei Ko, Kristin Y. Nguyen, Janko Kos, Kawaljit Kaur, Anahid Jewett, Paul Wong, Emanuela Senjor